FUNDED ON THE NATIONAL IMMUNISATION
PROGRAM FOR 70-79 YEAR OLDS ¹ †
HELP PROTECT YOUR 70-79 YEAR OLD PATIENTS FROM SHINGLES AND PHN 1 , 2
† AVAILABLE FOR 70 YEAR OLDS , WITH A TIME-LIMITED CATCH-UP PROGRAM FOR 71-79 YEAR OLDS 1
PHN = Postherpetic Neuralgia Hypothetical patient profile . May not be representative of every patient ’ s experience of shingles .
Before prescribing , please review the Product Information available at www . seqirus . com . au / PI
MINIMUM PRODUCT INFORMATION : ZOSTAVAX ® Zoster Virus Vaccine Live ( Oka / Merck ), Refrigerator stable Indications : Prevention of herpes zoster ( shingles ) in individuals 50 years of age and older . Prevention of postherpetic neuralgia ( PHN ) and reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older . * Contraindications : History of hypersensitivity to any component of the vaccine , including gelatin . History of anaphylactic / anaphylactoid reaction to neomycin . Primary and acquired immunodeficiency states due to conditions such as : acute and chronic leukaemias ; lymphoma ; other conditions affecting the bone marrow or lymphatic system ; immunosuppression due to HIV / AIDS ; cellular immune deficiencies . Immunosuppressive therapy including high-dose corticosteroids , but not topical / inhaled corticosteroids . ZOSTAVAX is a live , attenuated varicella-zoster vaccine and administration to individuals who are immunosuppressed or immunodeficient may result in disseminated varicella-zoster virus disease , including fatal outcomes . Active untreated tuberculosis . Pregnancy ( see PRECAUTIONS ). Precautions : Adequate treatment provisions , including adrenalin injection ( 1:1000 ), should be available for immediate use should an anaphylactic / anaphylactoid reaction occur . Consider deferral of vaccination in the presence of fever > 38.5 ° C . Safety and efficacy not established in adults known to be infected with HIV . Use in Pregnancy ( Category B2 ) Do not administer to pregnant females ; pregnancy should be avoided for 3 months after vaccination . Use in Lactation It is not known whether varicella-zoster virus is secreted in human milk . Use in the elderly The mean age of subjects enrolled in the largest ( N = 38,546 ) clinical study of ZOSTAVAX was 69 years ( range 59-99 years ). ZOSTAVAX was demonstrated to be generally safe and effective in this population . Interactions with other medicines : ZOSTAVAX can be administered concurrently with inactivated influenza vaccine . ZOSTAVAX and PNEUMOVAX 23 should not be given concomitantly because concomitant use resulted in reduced immunogenicity of ZOSTAVAX . Consider administration of the two vaccines separated by at least 4 weeks . Adverse Effects : headache , erythema , pain / tenderness , swelling , pruritus , fatigue , haematoma , warmth , induration , pain in extremity . Post-marketing experience : varicella , zoster , nausea , arthralgia , myalgia , injection-site rash , injection-site urticaria , pyrexia , transient injection-site lymphadenopathy , hypersensitivity including anaphylactic reactions , rash , necrotizing retinitis . Dosage and Administration : A single dose ( 0.65mL ) administered subcutaneously . Administer vaccine immediately after reconstitution to minimise loss of potency . ZOSTAVAX is not a treatment for zoster or PHN . Based on Approved Product Information dated 17 August 2017 .
* Please see change ( s ) in Product Information
PBS Information : This product is listed on the National Immunisation Program ( NIP ). Refer to schedule .
References : 1 . Department of Health . Immunise Australia Program . National Immunisation Program Schedule . Available at : https :// beta . health . gov . au / topics / immunisation / immunisation-throughout-life / nationalimmunisation-program-schedule . Accessed February 2018 . 2 . ZOSTAVAX ® Product Information , August 2017 . Product Information is available from Seqirus ( Australia ) Pty Ltd ABN : 66 120 398 067 63 Poplar Road , Parkville VIC 3052 www . seqirus . com . au ; distributor for Merck , Sharp and Dohme ( Australia ) Pty Ltd . CSL Medical Information : 1800 642 865 . ZOSTAVAX ® is a registered trademark of Merck & Co . Inc Whitehouse Station , NJ , USA . Seqirus™ is a trademark of Seqirus UK Limited or its affiliates . Date of preparation March 2018 . SEQ / ZOST / 0318 / 0302 . SEQ0260 / AD / FP .